triiodothyronine has been researched along with Papilledema in 1 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Papilledema: Swelling of the OPTIC DISK, usually in association with increased intracranial pressure, characterized by hyperemia, blurring of the disk margins, microhemorrhages, blind spot enlargement, and engorgement of retinal veins. Chronic papilledema may cause OPTIC ATROPHY and visual loss. (Miller et al., Clinical Neuro-Ophthalmology, 4th ed, p175)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To report a case of benign intracranial hypertension occurring during thyreostimulin suppression hormonotherapy after thyroidectomy for papillary cancer." | 1.31 | Benign intracranial hypertension and thyreostimulin suppression hormonotherapy. ( Conrath, J; Disdier, P; Dufour, H; Granel, B; Henry, JF; Serratrice, J; Weiller, PJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Serratrice, J | 1 |
| Granel, B | 1 |
| Conrath, J | 1 |
| Dufour, H | 1 |
| Disdier, P | 1 |
| Henry, JF | 1 |
| Weiller, PJ | 1 |
1 other study available for triiodothyronine and Papilledema
| Article | Year |
|---|---|
Benign intracranial hypertension and thyreostimulin suppression hormonotherapy.
Topics: Adenocarcinoma, Papillary; Drug Therapy, Combination; Female; Glycoproteins; Humans; Middle Aged; Pa | 2002 |